成纤维样滑膜细胞靶向抗体与类风湿关节炎一线治疗后未能达到早期和持续缓解或低疾病活动度相关
研究基于CareRA试验基线血清,筛选出3种新型抗体(抗UH-RA.305/318/329),在136例额外验证样本中分析其预测一线治疗后未达标的价值。这些抗体与第8周DAS28CRP/ESR缓解失败、SDAI/CDAI持续缓解失败及DAS28持续LDA失败相关,在RF/ACPA血清阴性患者中关联更强,并证实其靶向RA滑膜组织及SW982细胞中的成纤维样滑膜细胞。
要点
- 抗UH-RA.305/318/329抗体与第8周DAS28CRP缓解失败相关(OR 3.63,p=0.0031)。
- 在RF/ACPA血清阴性患者中,该抗体与第8周DAS28CRP缓解失败强关联(OR 17.3,p=0.0029)。
- 该抗体靶向RA滑膜组织及SW982细胞中的成纤维样滑膜细胞。
核心结论
- 研究识别出3种抗体生物标志物,与类风湿关节炎一线治疗后未能达到缓解或低疾病活动度相关。
研究设计与样本
- 从CareRA试验基线血清中筛选两个RA cDNA噬菌体展示文库,比较一线治疗后达到与未达到缓解的患者(各n=20)。
- 在136例额外CareRA参与者的基线样本中验证对UH-RA抗原的抗体反应性。
- 采用多变量分析研究新型抗体预测未达到缓解或低疾病活动度(LDA)的潜力,评估依据DAS28CRP/ESR和CDAI/SDAI。
- 通过免疫荧光确定抗体靶标在RA滑膜组织和成纤维样滑膜细胞系SW982中的存在。
主要发现
- 识别出针对41种新型抗原的抗体。
- 针对3种抗原中任一种(UH-RA.305/318/329)的抗体可区分未达到第8周DAS28CRP缓解与达到缓解的RA患者(36% vs 13%,p=0.0031)。
- 在所有患者中,抗UH-RA.305/318/329抗体反应性与未达到第8周DAS28CRP缓解(OR 3.63,p=0.0031)和DAS28ESR缓解(OR 2.92,p=0.016)相关。
- 该抗体与未达到SDAI/CDAI持续缓解相关(OR 5.59,两者p=0.039),与未达到DAS28CRP持续LDA(OR 3.7,p=0.009)和DAS28ESR持续LDA(OR 2.76,p=0.042)相关。
- 在RF/ACPA血清阴性患者中,这些抗体与未达到第8周DAS28CRP缓解强相关(OR 17.3,p=0.0029)。
关键数值与推荐
- 未达到第8周DAS28CRP缓解者中抗UH-RA.305/318/329抗体阳性率为36%,达到缓解者为13%(p=0.0031)。
- 所有患者中,抗UH-RA.305/318/329抗体与未达到第8周DAS28CRP缓解的OR为3.63(p=0.0031),与未达到第8周DAS28ESR缓解的OR为2.92(p=0.016)。
- 该抗体与未达到SDAI/CDAI持续缓解的OR均为5.59(p=0.039)。
- 该抗体与未达到DAS28CRP持续LDA的OR为3.7(p=0.009),与未达到DAS28ESR持续LDA的OR为2.76(p=0.042)。
- 在RF/ACPA血清阴性患者中,该抗体与未达到第8周DAS28CRP缓解的OR为17.3(p=0.0029)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To discover antibody biomarkers that can predict a lack of response to first-line therapy in rheumatoid arthritis (RA) patients. METHODS: Two RA cDNA phage display libraries were screened for novel antibodies in baseline RA sera from the Care in early RA (CareRA) trial, differentiating between patients who did or did not reach remission after first-line therapy (n=20 each). Antibody reactivity to identified University Hasselt (UH)-RA antigens was validated in baseline samples from 136 additional CareRA participants. The novel antibodies' potential to predict failure to reach remission or low disease activity (LDA), according to the Disease Activity Score 28-joint C-reactive protein/erythrocyte sedimentation rate (DAS28CRP/ESR) and Clinical/Simplified Disease Activity Index (CDAI/SDAI), was studied by multivariate analyses. The presence of the antibody targets in RA synovial tissue and the fibroblast-like synoviocyte (FLS) cell line SW982 was determined by immunofluorescence. RESULTS: We identified antibodies to 41 novel antigens. Antibodies against any of three antigens, UH-RA.305/318/329, discriminated between RA patients not reaching week (w)8 DAS28CRP remission and those that did (36% vs 13%,p=0.0031). In all patients, anti-UH-RA.305/318/329 antibody reactivity was associated with failure to reach week 8 DAS28CRP and DAS28ESR remission (OR 3.63,p=0.0031; OR 2.92,p=0.016; respectively), SDAI/CDAI sustained remission (OR 5.59,p=0.039 for both) and DAS28CRP and DAS28ESR sustained LDA (OR 3.7,p=0.009; OR 2.76,p=0.042; respectively). In rheumatoid factor/anti-citrullinated protein antibody (RF/ACPA) seronegative patients, these antibodies were strongly associated with failure to achieve week 8 DAS28CRP remission (OR 17.3,p=0.0029). Anti-UH-RA.305/329 antibodies were shown to target FLS in RA synovial tissue and SW982 cells. CONCLUSION: We identified three antibody biomarkers that are associated with failure to achieve remission/LDA after first-line RA therapy.
引用
- Vandormael P, Fadlallah S, Ruytinx P, et al. Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis. RMD Open. 2024. PMID: 39551578. doi:10.1136/rmdopen-2024-004743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。